Homeobox gene IRX1 is a tumor suppressor gene in gastric carcinoma

Oncogene

Volumn 29, Issue 27, 2010, Pages 3908-3920

  Guo, X ^a   Liu, W ^a   Pan, Y ^a   Ni, P ^b   Ji, J ^a   Guo, L ^a   Zhang, J ^a,a   Wu, J ^a   Jiang, J ^a   Chen, X ^a   Cai, Q ^a   Li, J ^a   Gu, Q ^a   Liu, B ^a   Zhu, Z ^a   Yu, Y ^a  

^a SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

epigenetic; gastric carcinoma; homeobox genes; IRX1; tumor suppressor

Indexed keywords

ANGIOGENIC FACTOR; HOMEODOMAIN PROTEIN; IRX1 PROTEIN; TUMOR MARKER; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL EXPERIMENT; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER INHIBITION; CANCER INVASION; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CARCINOGENICITY; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DNA METHYLATION; GENE AMPLIFICATION; GENE EXPRESSION; GENE FUNCTION; GENE IDENTIFICATION; GENE LOCUS; GENE MUTATION; GENE TARGETING; GENETIC TRANSFECTION; GENETIC VARIABILITY; HETEROZYGOSITY LOSS; HOMEOBOX; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; REAL TIME POLYMERASE CHAIN REACTION; STOMACH CARCINOMA; TUMOR SUPPRESSOR GENE;

ADULT; AGED; AGED, 80 AND OVER; ALLELES; ANIMALS; BASE SEQUENCE; CELL LINE, TUMOR; CHROMOSOMES, HUMAN, PAIR 5; DNA METHYLATION; DOWN-REGULATION; EPIGENESIS, GENETIC; FEMALE; GENE DOSAGE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HOMEODOMAIN PROTEINS; HUMANS; LOSS OF HETEROZYGOSITY; MALE; MICE; MICE, NUDE; MIDDLE AGED; PROMOTER REGIONS, GENETIC; STOMACH NEOPLASMS; TRANSCRIPTION FACTORS; TRANSFECTION;

EID: 77954539431     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2010.143     Document Type: Article

References (54)

1. Alarcon P, Rodriguez-Seguel E, Fernandez-Gonzalez A, Rubio R, Gomez-Skarmeta JL. (2008). A dual requirement for Iroquois genes during Xenopus kidney development. Development 135: 3197-3207.
2. Asaka S, Fujimoto T, Akaishi J, Ogawa K, Onda M. (2006). Genetic prognostic index influences patient outcome for node-positive breast cancer. Surg Today 36: 793-801.
3. Becker MB, Zulch A, Bosse A, Gruss P. (2001). Irx1 and Irx2 expression in early lung development. Mech Dev 106: 155-158.
4. Bennett KL, Karpenko M, Lin MT, Claus R, Arab K, Dyckhoff G et al. (2008). Frequently methylated tumor suppressor genes in head and neck squamous cell carcinoma. Cancer Res 68: 4494-4499.
5. Bergman Y, Mostoslavsky R. (1998). DNA demethylation: turning genes on. Biol Chem 379: 401-407.
6. Cairns P. (2009). 5'-azacytidine expression arrays. Methods Mol Biol 507: 165-174.
7. Choi IS, Wu TT. (2005). Epigenetic alterations in gastric carcino-genesis. Cell Res 15: 247-254.
8. Duffy MJ, Napieralski R, Martens JW, Span PN, Spyratos F, Sweep FC et al. (2009). Methylated genes as new cancer biomarkers. Eur J Cancer 45: 335-346.
9. Duggan DJ, Bittner M, Chen Y, Meltzer P, Trent JM. (1999). Expression profiling using cDNA microarrays. Nat Genet 21: 10-14. (Pubitemid 29031485)
10. Esteller M. (2007). Epigenetic gene silencing in cancer: the DNA hypermethylome. Hum Mol Genet 16(Spec No 1): R50-R59. (Pubitemid 47241842)
11. Ferguson CA, Tucker AS, Christensen L, Lau AL, Matzuk MM, Sharpe PT. (1998). Activin is an essential early mesenchymal signal in tooth development that is required for patterning of the murine dentition. Genes Dev 12: 2636-2649.
12. Garinis GA, Patrinos GP, Spanakis NE, Menounos PG. (2002). DNA hypermethylation: when tumour suppressor genes go silent. Hum Genet 111: 115-127.
13. Hao Y, Yu Y, Wang L, Yan M, Ji J, Qu Y et al. (2008). IPO-38 is identified as a novel serum biomarker of gastric cancer based on clinical proteomics technology. J Proteome Res 7: 3668-3677.
14. Hellebrekers DM, Melotte V, Vire E, Langenkamp E, Molema G, Fuks F et al. (2007). Identification of epigenetically silenced genes in tumor endothelial cells. Cancer Res 67: 4138-4148.
15. Huang Q, Chen W, Wang L, Lin W, Lin J, Lin X. (2008). Identification of transgelin as a potential novel biomarker for gastric adenocarcinoma based on proteomics technology. J Cancer Res Clin Oncol 134: 1219-1227.
16. Hurtubise A, Bernstein ML, Momparler RL. (2008). Preclinical evaluation of the antineoplastic action of 5-aza-2'-deoxycytidine and different histone deacetylase inhibitors on human Ewing's sarcoma cells. Cancer Cell Int 8: 16.
17. Ikeda Y, Hayashi I, Kamoshita E, Yamazaki A, Endo H, Ishihara K et al. (2004). Host stromal bradykinin B2 receptor signaling facilitates tumor-associated angiogenesis and tumor growth. Cancer Res 64: 5178-5185.
18. Iorns E, Lord CJ, Grigoriadis A, McDonald S, Fenwick K, Mackay A et al. (2009). Integrated functional, gene expression and genomic analysis for the identification of cancer targets. PLoS One 4: e5120.
19. Ishihara K, Hayash I, Yamashina S, Majima M. (2001). A potential role of bradykinin in angiogenesis and growth of S-180 mouse tumors. Jpn J Pharmacol 87: 318-326.
20. Ishihara K, Kamata M, Hayashi I, Yamashina S, Majima M. (2002). Roles of bradykinin in vascular permeability and angiogenesis in solid tumor. Int Immunopharmacol 2: 499-509.
21. Jee CD, Kim MA, Jung EJ, Kim J, Kim WH. (2009). Identification of genes epigenetically silenced by CpG methylation in human gastric carcinoma. Eur J Cancer 45: 1282-1293.
22. Jin G, Xu L, Shu Y, Tian T, Liang J, Xu Y et al. (2009). Common genetic variants on 5p15.33 contribute to risk of lung adenocarcinoma in a Chinese population. Carcinogenesis 30: 987-990.
23. Kamei M, Kato M, Mochizuki K, Kuroda K, Sato S, Hashizume S et al. (1992). Serodiagnosis of cancers by ELISA of anti-histone H2B antibody. Biotherapy 4: 17-22.
24. Kawakami K, Brabender J, Lord RV, Groshen S, Greenwald BD, Krasna MJ et al. (2000). Hypermethylated APC DNA in plasma and prognosis of patients with esophageal adenocarcinoma. J Natl Cancer Inst 92: 1805-1811.
25. Knudson AG. (1996). Hereditary cancer: two hits revisited. J Cancer Res Clin Oncol 122: 135-140.
26. Knudson AG. (2001). Two genetic hits (more or less) to cancer. Nat Rev Cancer 1: 157-162.
27. Kuga D, Mizoguchi M, Guan Y, Hata N, Yoshimoto K, Shono T et al. (2008). Prevalence of copy-number neutral LOH in glioblastomas revealed by genomewide analysis of laser-microdis-sected tissues. Neuro Oncol 10: 995-1003.
28. Lai IR, Lee WJ, Huang MT, Lin HH. (2002). Comparison of serum CA72-4, CEA, TPA, CA19-9 and CA125 levels in gastric cancer patients and correlation with recurrence. Hepatogastroenterology 49: 1157-1160.
29. Lemaire M, Chabot GG, Raynal NJ, Momparler LF, Hurtubise A, Bernstein ML et al. (2008). Importance of dose-schedule of 5-aza-20-deoxycytidine for epigenetic therapy of cancer. BMC Cancer 8: 128.
30. Lewis MT, Ross S, Strickland PA, Snyder CJ, Daniel CW. (1999). Regulated expression patterns of IRX-2, an Iroquois-class homeo-box gene, in the human breast. Cell Tissue Res 296: 549-554.
31. Lu Y, Yu Y, Zhu Z, Xu H, Ji J, Bu L et al. (2005). Identification of a new target region by loss of heterozygosity at 5p15.33 in sporadic gastric carcinomas: genotype and phenotype related. Cancer Lett 224: 329-337.
32. McKay JD, Hung RJ, Gaborieau V, Boffetta P, Chabrier A, Byrnes G et al. (2008). Lung cancer susceptibility locus at 5p15.33. Nat Genet 40: 1404-1406.
33. Momparler RL. (2003). Cancer epigenetics. Oncogene 22: 6479-6483.
34. Perez-Diez A, Morgun A, Shulzhenko N. (2007). Microarrays for cancer diagnosis and classification. Adv Exp Med Biol 593: 74-85.
35. Plendl J, Snyman C, Naidoo S, Sawant S, Mahabeer R, Bhoola KD. (2000). Expression of tissue kallikrein and kinin receptors in angiogenic microvascular endothelial cells. Biol Chem 381: 1103-1115.
36. Quackenbush J. (2006). Microarray analysis and tumor classification. N Engl J Med 354: 2463-2472.
37. Robertson KD, Jones PA. (2000). DNA methylation: past, present and future directions. Carcinogenesis 21: 461-467.
38. Ropiquet F, Huguenin S, Villette JM, Ronfle V, Le Brun G, Maitland NJ et al. (1999). FGF7/KGF triggers cell transformation and invasion on immortalised human prostatic epithelial PNT1A cells. Int J Cancer 82: 237-243.
39. Schneider-Stock R, Ocker M. (2007). Epigenetic therapy in cancer: molecular background and clinical development of histone deace-tylase and DNA methyltransferase inhibitors. IDrugs 10: 557-561.
40. Shaker S, Bernstein M, Momparler RL. (2004). Antineoplastic action of 5-aza-20-deoxycytidine. (Dacogen) and depsipeptide on Raji lymphoma cells. Oncol Rep 11: 1253-1256.
41. Shaoul R, Eliahu L, Sher I, Hamlet Y, Miselevich I, Goldshmidt O et al. (2006). Elevated expression of FGF7 protein is common in human gastric diseases. Biochem Biophys Res Commun 350: 825-833.
42. Tamura M, Gu J, Matsumoto K, Aota S, Parsons R, Yamada KM. (1998). Inhibition of cell migration, spreading, and focal adhesions by tumor suppressor PTEN. Science 280: 1614-1617.
43. Tamura M, Gu J, Takino T, Yamada KM. (1999). Tumor suppressor PTEN inhibition of cell invasion, migration, and growth: differential involvement of focal adhesion kinase and p130Cas. Cancer Res 59: 442-449.
44. Telford JL, Covacci A, Ghiara P, Montecucco C, Rappuoli R. (1994). Unravelling the pathogenic role of Helicobacter pylori in peptic ulcer: potential new therapies and vaccines. Trends Biotechnol 12: 420-426.
45. Tocchi A, Costa G, Lepre L, Liotta G, Mazzoni G, Cianetti A et al. (1998). The role of serum and gastric juice levels of carcinoem-bryonic antigen, CA19.9 and CA72.4 in patients with gastric cancer. J Cancer Res Clin Oncol 124: 450-455.
46. Tommasi S, Karm DL, Wu X, Yen Y, Pfeifer GP. (2009). Methylation of homeobox genes is a frequent and early epigenetic event in breast cancer. Breast Cancer Res 11: R14.
47. Toyota M, Issa JP. (2005). Epigenetic changes in solid and hematopoietic tumors. Semin Oncol 32: 521-530.
48. Tycko B. (2000). Epigenetic gene silencing in cancer. J Clin Invest 105: 401-407.
49. Ushijima T, Nakajima T, Maekita T. (2006). DNA methylation as a marker for the past and future. J Gastroenterol 41: 401-407.
50. van Tuyl M, Liu J, Groenman F, Ridsdale R, Han RN, Venkatesh V et al. (2006). Iroquois genes influence proximo-distal morphogenesis during rat lung development. Am J Physiol Lung Cell Mol Physiol 290: L777-L789.
51. Yamashita K, Upadhyay S, Osada M, Hoque MO, Xiao Y, Mori M et al. (2002). Pharmacologic unmasking of epigenetically silenced tumor suppressor genes in esophageal squamous cell carcinoma. Cancer Cell 2: 485-495. (Pubitemid 41043953)
52. Ychou M, Duffour J, Karma A, Gourgou S, Grenier J. (2000). Clinical significance and prognostic value of CA72-4 compared with CEA and CA19-9 in patients with gastric cancer. Dis Markers 16: 105-110.
53. Yu YY, Ji J, Lu Y, Bu L, Liu BY, Zhu ZG et al. (2006). [High-resolution analysis of chromosome 5 and identification of candidate genes in gastric cancer]. Zhonghua Zhong Liu Za Zhi 28: 84-87.
54. Zhao H, Kim Y, Wang P, Lapointe J, Tibshirani R, Pollack JR et al. (2005). Genome-wide characterization of gene expression variations and DNA copy number changes in prostate cancer cell lines. Prostate 63: 187-197.